Overall rank by patents
#31,738
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Gen1e Lifesciences Inc.
USPTO PatentsView assignee record - 8 granted patents across 5 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
8
Total patents granted
5
CPC technology areas
25.5
Avg claims per patent
-
5-year filing velocity
The verdict
Gen1e holds 8 US patents across 5 technology areas, rank #31,738 of 50,000 tracked assignees.
- #31,738
- of 50,000 US assignees by volume
- Top 13%
- by Innovation Score (50.5/100)
- 25.5
- avg claims per patent
Portfolio overview
Gen1e Lifesciences Inc. has been granted 8 US utility patents between 2022 and 2025, placing Gen1e Lifesciences Inc. at rank #31,738 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 25.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Gen1e Lifesciences Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Gen1e sits between GE Aviation Czech S.r.o. (8 patents, rank #31,734) and Genereach Biotechnology Corporation (8 patents, rank #31,742) - the closest US assignees by grant volume. The composite Innovation Score of 50.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 8 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Gen1e Lifesciences Inc.'s 25.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Gen1e Lifesciences Inc. against peers pursuing similar technology classes.
Who files at Gen1e's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- GE Aviation Czech…
GE AVIATION CZECH S.R.O.
8 patents
- GE Intellectual P…
GE Intellectual Property Licensing, LLC
8 patents
- GEA Westfalia Sep…
GEA Westfalia Separator Group GmbH
8 patents
- GEE HOO Fitec
GEE HOO FITEC CORP.
8 patents
- GENE Stream PTY
GENE STREAM PTY LTD.
8 patents
- General Plasma
GENERAL PLASMA INC.
8 patents
- General Printing…
GENERAL PRINTING & DESIGN, INC.
8 patents
- Genereach Biotech…
GENEREACH BIOTECHNOLOGY CORPORATION
8 patents
- Gen1e Lifesciences ◀
GEN1E LIFESCIENCES INC.
8 patents
What this shows Gen1e holds 8 patents at rank #31,738, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Gen1e
By rank, the assignees closest to #31,738 in granted patent volume.
- GE Aviation Czech S.r.o. #31,734 · 8 patents
- GE Intellectual Property Licensing, Llc #31,735 · 8 patents
- GEA Westfalia Separator Group Gmbh #31,736 · 8 patents
- GEE HOO Fitec Corp. #31,737 · 8 patents
- GENE Stream PTY Ltd. #31,739 · 8 patents
- General Plasma Inc. #31,740 · 8 patents
- General Printing & Design, Inc. #31,741 · 8 patents
- Genereach Biotechnology Corporation #31,742 · 8 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Gen1e's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Gen1e's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
51 Top 13% higher than 87% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 3 | 37.5% |
| 2023 | 1 | 12.5% |
| 2024 | 2 | 25.0% |
| 2025 | 2 | 25.0% |
Which technologies does Gen1e Lifesciences Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Gen1e Lifesciences Inc. hold?
Gen1e Lifesciences Inc. holds 8 US granted patents filed between 2022 and 2025, spanning 5 technology areas.
What is Gen1e Lifesciences Inc.'s Innovation Score?
Gen1e Lifesciences Inc. has an Innovation Score of 50.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Gen1e Lifesciences Inc. focus on?
Gen1e Lifesciences Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 8 patents. The company has filed patents in 5 CPC subclasses total.
Is Gen1e Lifesciences Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Gen1e Lifesciences Inc..
What does claim depth mean for Gen1e Lifesciences Inc.'s patents?
Gen1e Lifesciences Inc.'s patents average 25.5 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Gen1e Lifesciences Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Gen1e's 8 grants land it in the top 13% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Gen1e ranks #31,738 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.